Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.
China Resources Pharmaceutical Group Limited has scheduled a board meeting for 24 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also consider whether to recommend a final dividend, a decision that will be closely watched by investors for signals on profitability, cash flow strength and the company’s capital-return policy.
The timing of the meeting indicates the company is moving ahead on its regular financial reporting cycle, providing the market with clarity on its full-year performance. Any dividend proposal emerging from the meeting could influence shareholder returns and market sentiment, particularly against the backdrop of competition and regulatory changes in China’s pharmaceutical industry.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company engaged in the research, manufacture and distribution of pharmaceutical products and related healthcare services. The group operates through a network of subsidiaries, serving medical institutions and retail markets in mainland China and the broader regional healthcare sector.
Average Trading Volume: 9,238,292
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.52B
See more data about 3320 stock on TipRanks’ Stock Analysis page.